These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 26080803)
1. From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression. Chamard-Jovenin C; Jung AC; Chesnel A; Abecassis J; Flament S; Ledrappier S; Macabre C; Boukhobza T; Dumond H BMC Syst Biol; 2015 Jun; 9():28. PubMed ID: 26080803 [TBL] [Abstract][Full Text] [Related]
2. Expression and localization of estrogen receptor in human breast cancer and its clinical significance. Li L; Wang Q; Lv X; Sha L; Qin H; Wang L; Li L Cell Biochem Biophys; 2015 Jan; 71(1):63-8. PubMed ID: 25113640 [TBL] [Abstract][Full Text] [Related]
3. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer. Garan LAW; Xiao Y; Lin WC Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2209211119. PubMed ID: 36252018 [TBL] [Abstract][Full Text] [Related]
4. The Role of ERα36 in Development and Tumor Malignancy. Thiebaut C; Konan HP; Guerquin MJ; Chesnel A; Livera G; Le Romancer M; Dumond H Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32526980 [TBL] [Abstract][Full Text] [Related]
5. Clinical and Biological Significance of Nagel A; Szade J; Iliszko M; Elzanowska J; Welnicka-Jaskiewicz M; Skokowski J; Stasilojc G; Bigda J; Sadej R; Zaczek A; Markiewicz A Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995757 [TBL] [Abstract][Full Text] [Related]
6. ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells. Notas G; Panagiotopoulos A; Vamvoukaki R; Kalyvianaki K; Kiagiadaki F; Deli A; Kampa M; Castanas E Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299224 [TBL] [Abstract][Full Text] [Related]
7. Tamoxifen enhances stemness and promotes metastasis of ERα36 Wang Q; Jiang J; Ying G; Xie XQ; Zhang X; Xu W; Zhang X; Song E; Bu H; Ping YF; Yao XH; Wang B; Xu S; Yan ZX; Tai Y; Hu B; Qi X; Wang YX; He ZC; Wang Y; Wang JM; Cui YH; Chen F; Meng K; Wang Z; Bian XW Cell Res; 2018 Mar; 28(3):336-358. PubMed ID: 29393296 [TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer. Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000 [TBL] [Abstract][Full Text] [Related]
9. Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics. Mahboobifard F; Bidari-Zerehpoosh F; Davoudi Z; Panahi M; Dargahi L; Pourgholami MH; Sharifi G; Izadi N; Jorjani M Pituitary; 2020 Jun; 23(3):232-245. PubMed ID: 32026205 [TBL] [Abstract][Full Text] [Related]
10. Mammary epithelial cell phenotype disruption in vitro and in vivo through ERalpha36 overexpression. Thiebaut C; Chamard-Jovenin C; Chesnel A; Morel C; Djermoune EH; Boukhobza T; Dumond H PLoS One; 2017; 12(3):e0173931. PubMed ID: 28301550 [TBL] [Abstract][Full Text] [Related]
11. The elevated level of ERα36 is correlated with nodal metastasis and poor prognosis in lung adenocarcinoma. Zhang S; Qiu C; Wang L; Liu Q; Du J Steroids; 2014 Sep; 87():39-45. PubMed ID: 24928730 [TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. Wu JR; Zhao Y; Zhou XP; Qin X Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575 [TBL] [Abstract][Full Text] [Related]
13. Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells. Thiebaut C; Chesnel A; Merlin JL; Chesnel M; Leroux A; Harlé A; Dumond H Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31146345 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer. Wang ZY; Yin L Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453 [TBL] [Abstract][Full Text] [Related]
15. Estrogen signaling and estrogen receptors as prognostic indicators in laryngeal cancer. Verma A; Schwartz N; Cohen DJ; Boyan BD; Schwartz Z Steroids; 2019 Dec; 152():108498. PubMed ID: 31539535 [TBL] [Abstract][Full Text] [Related]
16. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen. Liu R; Guo CX; Zhou HH Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514 [TBL] [Abstract][Full Text] [Related]
17. A Role for Estrogen Receptor alpha36 in Cancer Progression. Pagano MT; Ortona E; Dupuis ML Front Endocrinol (Lausanne); 2020; 11():506. PubMed ID: 32849292 [TBL] [Abstract][Full Text] [Related]
18. Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. Cohen DJ; Patel V; Verma A; Boyan BD; Schwartz Z Steroids; 2019 Feb; 142():28-33. PubMed ID: 29133279 [TBL] [Abstract][Full Text] [Related]
19. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer. Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377 [No Abstract] [Full Text] [Related]
20. The role of ERα36 in cell type-specific functions of estrogen and cancer development. Mahboobifard F; Dargahi L; Jorjani M; Ramezani Tehrani F; Pourgholami MH Pharmacol Res; 2021 Jan; 163():105307. PubMed ID: 33246174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]